KR870010196A - 프리(pre)-S 유전자 코우드된 펩티드, B형 간염면역 원, 왁찐, 진단법 및 합성지질소낭 담체 - Google Patents

프리(pre)-S 유전자 코우드된 펩티드, B형 간염면역 원, 왁찐, 진단법 및 합성지질소낭 담체 Download PDF

Info

Publication number
KR870010196A
KR870010196A KR870004112A KR870004112A KR870010196A KR 870010196 A KR870010196 A KR 870010196A KR 870004112 A KR870004112 A KR 870004112A KR 870004112 A KR870004112 A KR 870004112A KR 870010196 A KR870010196 A KR 870010196A
Authority
KR
South Korea
Prior art keywords
peptide
hepatitis
immunogen
peptide immunogen
diagnostics
Prior art date
Application number
KR870004112A
Other languages
English (en)
Other versions
KR900006574B1 (ko
Inventor
로버트 뉴래스 알렉산더
비. 에이취. 켄트 스테판
Original Assignee
원본미기재
뉴욕 블러드 센터 인코오퍼레이티드
캘리포니아 인스티튜트 오브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 뉴욕 블러드 센터 인코오퍼레이티드, 캘리포니아 인스티튜트 오브 테크놀로지 filed Critical 원본미기재
Publication of KR870010196A publication Critical patent/KR870010196A/ko
Application granted granted Critical
Publication of KR900006574B1 publication Critical patent/KR900006574B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/223—Hepatitis related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

프리(pre)-S 유전자 코우드된 펩티드, B형 간염면역 원, 왁찐, 진단법 및 합성지질소낭 담체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 폴리펩티드 성분으로 분해된 환원된 HBsAg를 요소내에서 SDS-폴리아크릴아미드겔 전기영동(“SDS-PAGE”)에 따르게 한 결과를 나타내며,
제2도는 HBV DNA 의 서열로부터 유도된 프리-S 유전자 영역의 번역생성물의 아미노산 서열을 나타낸다.
서열은 한글자의 아미노산 코우드로 나타내며 (이러한 코우드는 본명세서 ‘정의’난에 기재하였다) 5가지 별개의 HBV 아형(亞型)에 대한 서열을 제시하였다.
6번째 밑줄을 모든 5가지 아형에 공통인 아미노산 잔기를 나타낸다.
제3도는 프리-S 유전자 생성물의 아미노산 서열에 해당하는 상대적인 친수성의 단면도를 나타낸다.
ayw 이외의 아형에 대한 단면도도 이와 유사하다. 메티오닌 175로부터 오른쪽의 단면부분은 S-유전자 번역 생성물을 나타낸다.

Claims (8)

  1. HBV의 외피의 프리-S유전자코우드된 영역내에 적어도 6연속 아미노산에 해당하는 아미노산 사슬을 포함하는 펩티드로 이루어지는 B형간염 펩티드 면역원에 있어서, B형간염 바이러스의 천연발생 외피 단백질에 해당하는 아미노산 서열이 없는 상기 펩티드 면역원으로서, 여기서 펩티드는 프리-S(12-47), 프리-S(21-47), 프리-S(120-153), 프리 -S(132-137), 프리 -S(53-73) 및 프리-S(128-139)로 구성되는 군으로부터 선택되는 것을 특징으로 하는 B형 간염 펩티드 면역원.
  2. 제1항에 있어서, 상기 펩티드는 프리-S(12-47)인 것을 특징으로 하는 B형 간염 펩티드 면역원.
  3. 제1항에 있어서, 상기 펩티드는 프리-S(21-47)인 것을 특징으로 하는 B형 간염 펩티드 면역원.
  4. 제1항에 있어서, 상기 펩티드는 프리-S(120-153)인 것을 특징으로 하는 B형 간염 펩티드 면역원.
  5. 제1항에 있어서, 상기 펩티드는 프리-S(132-137)인 것을 특징으로 하는 B형 간염 펩티드 면역원.
  6. 제1항에 있어서, 상기 펩티드는 프리-S(53-73)인 것을 특징으로 하는 B형 간염 펩티드 면역원.
  7. 제1항에 있어서, 상기 펩티드는 프리-S(128-139)인 것을 특징으로 하는 B형 간염 펩티드 면역원.
  8. (a) 바이러스의 외피유전자 생성물에 해당하는 복수의 다른 펩티드를 합성하는 단계와,
    (b) (a)단계의 펩티드에 대한 항체를 기르는 단계,
    (c) 펩티드가 세포 바이러스 수용체에 결합하는지와 펩티드와 항펩티드항체가 바이러스와 세포표면의 반응을 억제하는지를 확인하는 단계로 이루어지는 것을 특징으로 하는 펩티드가 바이러스 중화항체를 유도할 것인지를 결정하는 방법.
    ※ 참고사항: 최초출원 내용에 의하여 공개하는 것임.
KR1019870004112A 1986-04-28 1987-04-28 프리(pre)-S 유전자 코우드된 펩티드, B형 간염면역원, 왁찐, 진단법 및 합성지질소낭 담체 KR900006574B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US856522 1986-04-28
US06/856,522 US4861588A (en) 1985-02-05 1986-04-28 Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers

Publications (2)

Publication Number Publication Date
KR870010196A true KR870010196A (ko) 1987-11-30
KR900006574B1 KR900006574B1 (ko) 1990-09-13

Family

ID=25323838

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870004112A KR900006574B1 (ko) 1986-04-28 1987-04-28 프리(pre)-S 유전자 코우드된 펩티드, B형 간염면역원, 왁찐, 진단법 및 합성지질소낭 담체

Country Status (9)

Country Link
US (1) US4861588A (ko)
EP (2) EP0243913A3 (ko)
JP (1) JPS6345226A (ko)
KR (1) KR900006574B1 (ko)
CN (1) CN87102945A (ko)
AU (2) AU602894B2 (ko)
CA (1) CA1283602C (ko)
DK (1) DK213987A (ko)
ZA (1) ZA872165B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415800A (en) * 1981-08-24 1983-11-15 International Business Machines Corporation Method and apparatus for monitoring and controlling heated fusers for copiers
JP2758184B2 (ja) * 1987-06-22 1998-05-28 メデバ ホールディングス ベスローテン ベノートスハップ 肝炎ｂ表面抗原ワクチン
US5290562A (en) * 1987-11-27 1994-03-01 L V M H Recherche Compositions and methods employing liposomes including tyrosine or a tyrosine derivative
EP0326111A3 (en) * 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
EP0328123A1 (en) * 1988-02-09 1989-08-16 Eugene Tech International, Inc. Heterogeneous, pre-S rich hepatitis B surface antigen
IL91335A0 (en) * 1988-08-16 1990-03-19 Univ Yale Dna sequence and hepadnavirus
FR2637184A1 (fr) * 1988-10-05 1990-04-06 Inst Nat Sante Rech Med Anticorps monoclonal reconnaissant une region pre-s1 de la grande proteine d'enveloppe du virus de l'hepatite b et ses applications, notamment pour le diagnostic in vitro et le traitement de l'hepatite b
US5439792A (en) * 1989-06-02 1995-08-08 Genetic Systems Corporation Cysteine thiol-protected peptides for use in immunoassays
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
US5576175A (en) * 1989-09-20 1996-11-19 Immuno Aktiengesellschaft Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
JPH03152467A (ja) * 1989-11-09 1991-06-28 Nitsusui Seiyaku Kk ＨＢｓ抗体測定試薬
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
PT97632A (pt) * 1990-05-11 1992-03-31 Scripps Clinic Res Processo de obtencao de polipeptidos relacionados com a proteina do antigenio de superficie do virus da hepatite b e de vacinas que os contem
US5147652A (en) * 1990-07-03 1992-09-15 Cell Research Corporation Autobiotics and their use in eliminating nonself cells in vivo
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
DE69232871T2 (de) * 1991-06-24 2003-05-08 Chiron Corp Polypeptide des hepatitis c-virus (hiv)
US5736378A (en) * 1991-09-12 1998-04-07 The Scripps Research Institute Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR
CN1065142C (zh) * 1992-01-14 2001-05-02 麦迪瓦赫丁公司 组合物用作慢性病毒性肝脏疾病治疗剂的应用
US5980899A (en) * 1992-06-10 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5929220A (en) * 1995-07-21 1999-07-27 The General Hospital Corporation Hepadnavirus receptor
US6068981A (en) * 1997-10-03 2000-05-30 Biocode, Inc. Marking of orally ingested products
EP1281761A1 (en) 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
AU2002359327A1 (en) * 2001-10-30 2003-05-12 Thomas Jefferson University Method of treating viral infections
ES2428630T3 (es) * 2004-09-22 2013-11-08 Advanced Life Science Institute, Inc. Método para detectar el antígeno s del virus de la hepatitis B
CN105842447B (zh) * 2016-03-18 2017-12-15 南昌大学 一种针对乙肝表面抗原的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867517A (en) * 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
US4415491A (en) * 1980-01-14 1983-11-15 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
ZA831547B (en) * 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
JPS58194897A (ja) * 1982-05-07 1983-11-12 Takeda Chem Ind Ltd 新規ｄｎａ，その製造方法およびそれで形質転換させた宿主
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
JPS6137738A (ja) * 1984-07-31 1986-02-22 Tetsuo Nakamura Ｂ型肝炎ワクチン
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants

Also Published As

Publication number Publication date
DK213987A (da) 1987-10-29
DK213987D0 (da) 1987-04-27
AU7197887A (en) 1987-10-29
EP0243913A3 (en) 1988-08-10
AU602894B2 (en) 1990-11-01
ZA872165B (en) 1988-03-30
EP0243913A2 (en) 1987-11-04
US4861588A (en) 1989-08-29
AU6461390A (en) 1991-01-03
KR900006574B1 (ko) 1990-09-13
JPS6345226A (ja) 1988-02-26
CN87102945A (zh) 1988-04-20
EP0485361A1 (en) 1992-05-13
CA1283602C (en) 1991-04-30

Similar Documents

Publication Publication Date Title
KR870010196A (ko) 프리(pre)-S 유전자 코우드된 펩티드, B형 간염면역 원, 왁찐, 진단법 및 합성지질소낭 담체
RU2212899C2 (ru) Hcv иммунореактивные полипептидные композиции
Stibbe et al. Structural relationships between minor and major proteins of hepatitis B surface antigen
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
RU98117084A (ru) Hcv иммунореактивные полипептидные композиции
ATE175121T1 (de) Durch pre-s-gen kodierte hepatitis-b-peptid- immunogene, vakzine, diagnostika und synthetische lipid-bläschenträger
EP0271302A3 (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
DE69030124D1 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus
DE69433971D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
DK532184A (da) Antigene aminosyresekvenser
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
ATE173275T1 (de) Von einem retrovirus aus der hiv-gruppe abgeleitete peptide und deren verwendung
DE3582284D1 (de) Hepatitis-b-impfstoff.
KR890005270A (ko) 재조합 종두 비루스
DE69013471D1 (de) Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
BR8700563A (pt) Processo para produzir um polipeptideo selecionado em uma celula de inseto hospedeira adequada;vetor recombinador,celula de inseto infectada,peptideo;molecula de polipeptideo;processo para produzir antigeno de superficie de virus de hepatite b em uma celula de inseto hospedeira adequada;celula de inseto hospedeira modificada,antigeno de superficie de virus de hepatite b
KR910016347A (ko) C형 간염 바이러스에 대한 초면역 글로블린 및 이의 제조방법
KR940021732A (ko) C형 간염 바이러스의 비구조 4 부분 단백질의 발현
KR960034420A (ko) 적어도 2개의 c형간염바이러스관련펩티드로 이루어진 다량체항원펩티드
RU97115378A (ru) Асиалогликопротеины вируса гепатита с
KR970010787A (ko) B형 간염 바이러스 표면항원과 c형 간염 바이러스 외피 단백질의 융합 단백질 및 이를 포함하는 혼합 백신
KR940021575A (ko) 씨(c)형 간염 바이러스의 비구조 5-1.2 단백질의 제조방법
TH4148A (th) Dna ชนิดใหม่และโพลิเพนไทด์
KR950000883A (ko) 한국에서 분리한 신규한 c형 간염 바이러스 유전자
TH1016A (th) การประดิษฐ์และการใช้กรดดีออกซีไรโบนิวคลีอิค(กรรมวิธี)

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19930826

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee